Walleye Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.46M | Sell |
27,500
-51,196
| -65% | -$6.43M | 0.01% | 480 |
|
|
2025
Q1 | $8.7M | Buy |
78,696
+69,737
| +778% | +$7.71M | 0.04% | 239 |
|
|
2024
Q4 | $1.22M | Sell |
8,959
-79,187
| -90% | -$10.8M | ﹤0.01% | 869 |
|
|
2024
Q3 | $10.2M | Buy |
88,146
+83,559
| +1,822% | +$9.63M | 0.02% | 264 |
|
|
2024
Q2 | $631K | Buy |
4,587
+4,037
| +734% | +$556K | ﹤0.01% | 1349 |
|
|
2024
Q1 | $75.9K | Buy |
+550
| New | +$75.9K | ﹤0.01% | 2064 |
|
|
2023
Q4 | – | Sell |
-30,713
| Closed | -$3.46M | – | 2714 |
|
|
2023
Q3 | $3.46M | Buy |
+30,713
| New | +$3.46M | 0.01% | 487 |
|
|
2023
Q2 | – | Sell |
-15,161
| Closed | -$1.53M | – | 2580 |
|
|
2023
Q1 | $1.53M | Buy |
+15,161
| New | +$1.53M | 0.02% | 604 |
|
|
2022
Q2 | – | Sell |
-25,533
| Closed | -$2.39M | – | 2539 |
|
|
2022
Q1 | $2.39M | Sell |
25,533
-2,849
| -10% | -$267K | 0.06% | 307 |
|
|
2021
Q4 | $2.42M | Buy |
28,382
+24,582
| +647% | +$2.09M | 0.08% | 281 |
|
|
2021
Q3 | $364 | Sell |
3,800
-4,187
| -52% | -$401 | 0.01% | 905 |
|
|
2021
Q2 | $777 | Buy |
+7,987
| New | +$777 | 0.03% | 531 |
|
|
2020
Q2 | – | Sell |
-1,734
| Closed | -$150K | – | 722 |
|
|
2020
Q1 | $150K | Sell |
1,734
-7,094
| -80% | -$614K | 0.03% | 325 |
|
|
2019
Q4 | $949K | Buy |
8,828
+6,191
| +235% | +$666K | 0.06% | 120 |
|
|
2019
Q3 | $238K | Buy |
+2,637
| New | +$238K | 0.01% | 175 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 755 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 523 |
|